Landmark DECIDE Registry Data Demonstrate Impact of Heartflow Plaque Analysis on Coronary Artery Disease Medical Management. Click to read press release.

Confident CAD management
starts with plaque quantification. 

Heartflow Plaque Staging* is
Backed by Evidence.

With outcomes from over 2,800 patients, Heartflow Plaque Staging* is the leading tool for patient risk stratification based on total plaque volume.1

Heartflow Plaque Staging*
Personalizes Individual Cardiac Risk

Heartflow Plaque Stage (mm3)
plaque staging chartGraphs showing percent without events.

† Controlling for risk factors, stenosis, and FFRCT.

Built for Action

Medical management recommendations developed by preventive cardiology and CCTA expert consensus are being studied in the DECIDE Registry, the largest prospective registry on plaque analysis.2

Overall considerations: Consider GLP1 treatment if BMI>27 kg/m2 | Lifestyle modifications guidance especially in higher stages.

StageTotal Plaque Volume

Lipid Biomarkers

Thresholds/Goals

Medical Management

Currently under clinical evaluation.
Mild‡1-100
  • LDL-C: 100 mg/dL
  • Non-HDL: 130 mg/dL
  • Apo-B: 90 mg/dL
  • Statin
  • ± Aspirin
Moderate‡>101-250
  • LDL-C: 70 mg/dL
  • Non-HDL: 100 mg/dL
  • Apo-B: 70 mg/dL
  • High intensity statin ± PCSK9I ± Bempedoic Acid ± Ezetimibe
  • ± Aspirin
  • If DM: Intensify therapy with GLP1 ± SGLT2I
Severe‡>251-750
  • LDL-C: 55 mg/dL
  • Non-HDL: 85 mg/dL
  • Apo-B: 60 mg/dL
  • High intensity statin ± PCSK9I ± Bempedoic Acid ± Ezetimibe
  • Aspirin
  • Aggressive BP Rx
  • If DM: Intensify therapy with GLP1 ± SGLT2I
  • If elevated BMI: weight loss treatment
  • If elevated CRP & LDL at target: consider anti-inflammatories
Extensive<750

All as low as can be achieved:

  • LDL-C: <50 mg/dL
  • Non-HDL: <80 mg/dL
  • Apo-B: <50 mg/dL
  • Same as severe
  • ± Colchicine ± Icosapent Ethyl

‡Consider intensifying to next stage if nomogram percentile >50th and/or risk enhancers.3

‡Consider intensifying to next stage if nomogram percentile >50th and/or risk enhancers.3

Measurable Patient Impact

For the first time, modeled outcomes show the risk of CV events could decrease when Heartflow Plaque Staging* guides care.4

18.7mg/dL

Decrease in LDL-C with Plaque Staging* led management

~15%

Suggested decrease in risk of cardiac events based on average LDL-C decrease1